Ponatinib enhances anticancer drug sensitivity in MRP7-overexpressing cells

Sun,Yue-Li; Kumar,Priyank; Sodani,Kamlesh; Patel,Atish; Pan,Yihang; Baer,Maria R.; Chen,Zhe-Sheng; Jiang,Wen-Qi

doi:10.3892/or.2014.3002

Ponatinib enhances anticancer drug sensitivity in MRP7-overexpressing cells

Authors:
- Yue-Li Sun
- Priyank Kumar
- Kamlesh Sodani
- Atish Patel
- Yihang Pan
- Maria R. Baer
- Zhe-Sheng Chen
- Wen-Qi Jiang
View Affiliations

Affiliations: State Key Laboratory of Oncology in South China, Guangzhou, Guangdong, P.R. China, Department of Pharmaceutical Sciences, College of Pharmacy and Allied Health Professionals, St. John's University, Queens, New York, NY 11439, USA, Cytogenetics Laboratory, Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY, USA, University of Maryland Greenebaum Cancer Center and Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA, Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong 510060, P.R. China
Published online on: January 28, 2014 https://doi.org/10.3892/or.2014.3002
Pages: 1605-1612

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The presence of acquired multidrug resistance (MDR) is one of the primary impediments to the success of chemotherapy. MDR is often a result of overexpression of ATP-binding cassette (ABC) transporters, which are involved in the extrusion of therapeutic drugs. Recently, it was shown that several ABC transporters could be modulated by specific tyrosine-kinase inhibitors (TKIs). Ponatinib, a multi-targeted TKI, inhibits the activity of BCR-ABL with very high potency and broad specificity, including the T315I mutation which confers resistance to other TKIs. It was reported that ponatinib was capable of reversing breast cancer resistance protein (BCRP)- and P-glycoprotein (P-gp)-mediated MDR. In the present study, we report for the first time that ponatinib also potentiates the cytotoxicity of widely used therapeutic substrates of MRP7, such as paclitaxel, docetaxel, vincristine and vinblastine. Ponatinib significantly enhances the accumulation of [3H]-paclitaxel in cells expressing MRP7. Furthermore, accumulation of [3H]-paclitaxel was achieved by inhibition of MRP7-mediated transport. Ponatinb limited drug export via MRP7 by multiple mechanisms. In addition to inhibition of pump function, ponatinib also downregulated MRP7 protein expression in a time- and concentration-dependent manner. Thus, ponatinib may represent a potential reversal agent for the treatment of MDR and may be useful for combination therapy in MDR cancer patients in clinical practice.

View Figures

View References

1	Goldman JM: Ponatinib for chronic myeloid leukemia. N Engl J Med. 367:2148–2149. 2012. View Article : Google Scholar : PubMed/NCBI
2	Gromicho M, Dinis J, Magalhaes M, et al: Development of imatinib and dasatinib resistance: dynamics of expression of drug transporters ABCB1, ABCC1, ABCG2, MVP, and SLC22A1. Leuk Lymphoma. 52:1980–1990. 2011. View Article : Google Scholar : PubMed/NCBI
3	Breccia M and Alimena G: Refining targeted therapies in chronic myeloid leukemia: development and application of nilotinib, a step beyond imatinib. Onco Targets Ther. 1:49–58. 2008. View Article : Google Scholar : PubMed/NCBI
4	Shah NP, Nicoll JM, Nagar B, et al: Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell. 2:117–125. 2002. View Article : Google Scholar
5	Cortes JE, Kantarjian H, Shah NP, et al: Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Engl J Med. 367:2075–2088. 2012. View Article : Google Scholar
6	Jones PM and George AM: The ABC transporter structure and mechanism: perspectives on recent research. Cell Mol Life Sci. 61:682–699. 2004. View Article : Google Scholar : PubMed/NCBI
7	Davidson AL, Dassa E, Orelle C and Chen J: Structure, function, and evolution of bacterial ATP-binding cassette systems. Microbiol Mol Biol Rev. 72:317–364. 2008. View Article : Google Scholar : PubMed/NCBI
8	Sun YL, Patel A, Kumar P and Chen ZS: Role of ABC transporters in cancer chemotherapy. Chin J Cancer. 31:51–57. 2012. View Article : Google Scholar
9	Szakacs G, Varadi A, Ozvegy-Laczka C and Sarkadi B: The role of ABC transporters in drug absorption, distribution, metabolism, excretion and toxicity (ADME-Tox). Drug Discov Today. 13:379–393. 2008. View Article : Google Scholar : PubMed/NCBI
10	Brozik A, Hegedus C, Erdei Z, et al: Tyrosine kinase inhibitors as modulators of ATP binding cassette multidrug transporters: substrates, chemosensitizers or inducers of acquired multidrug resistance? Expert Opin Drug Metab Toxicol. 7:623–642. 2011. View Article : Google Scholar
11	Hegedus T, Orfi L, Seprodi A, Varadi A, Sarkadi B and Keri G: Interaction of tyrosine kinase inhibitors with the human multidrug transporter proteins, MDR1 and MRP1. Biochim Biophys Acta. 1587:318–325. 2002. View Article : Google Scholar : PubMed/NCBI
12	Ozvegy-Laczka C, Hegedus T, Varady G, et al: High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter. Mol Pharmacol. 65:1485–1495. 2004. View Article : Google Scholar : PubMed/NCBI
13	Hegedus C, Ozvegy-Laczka C, Apati A, et al: Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties. Br J Pharmacol. 158:1153–1164. 2009. View Article : Google Scholar : PubMed/NCBI
14	Burger H, van Tol H, Boersma AW, et al: Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood. 104:2940–2942. 2004. View Article : Google Scholar : PubMed/NCBI
15	Brendel C, Scharenberg C, Dohse M, et al: Imatinib mesylate and nilotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cells. Leukemia. 21:1267–1275. 2007. View Article : Google Scholar : PubMed/NCBI
16	Shen T, Kuang YH, Ashby CR, et al: Imatinib and nilotinib reverse multidrug resistance in cancer cells by inhibiting the efflux activity of the MRP7 (ABCC10). PLoS One. 4:e75202009. View Article : Google Scholar : PubMed/NCBI
17	Tiwari AK, Sodani K, Wang SR, et al: Nilotinib (AMN107, Tasigna) reverses multidrug resistance by inhibiting the activity of the ABCB1/Pgp and ABCG2/BCRP/MXR transporters. Biochem Pharmacol. 78:153–161. 2009. View Article : Google Scholar : PubMed/NCBI
18	Tiwari AK, Sodani K, Dai CL, et al: Nilotinib potentiates anticancer drug sensitivity in murine ABCB1-, ABCG2-, and ABCC10-multidrug resistance xenograft models. Cancer Lett. 328:307–317. 2013. View Article : Google Scholar : PubMed/NCBI
19	Dai CL, Tiwari AK, Wu CP, et al: Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2. Cancer Res. 68:7905–7914. 2008. View Article : Google Scholar : PubMed/NCBI
20	Kuang YH, Shen T, Chen X, et al: Lapatinib and erlotinib are potent reversal agents for MRP7 (ABCC10)-mediated multidrug resistance. Biochem Pharmacol. 79:154–161. 2010. View Article : Google Scholar : PubMed/NCBI
21	Sen R, Natarajan K, Bhullar J, et al: The novel BCR-ABL and FLT3 inhibitor ponatinib is a potent inhibitor of the MDR-associated ATP-binding cassette transporter ABCG2. Mol Cancer Ther. 11:2033–2044. 2012. View Article : Google Scholar : PubMed/NCBI
22	Malofeeva EV, Domanitskaya N, Gudima M and Hopper-Borge EA: Modulation of the ATPase and transport activities of broad-acting multidrug resistance factor ABCC10 (MRP7). Cancer Res. 72:6457–6467. 2012. View Article : Google Scholar : PubMed/NCBI
23	Hopper-Borge EA, Churchill T, Paulose C, et al: Contribution of Abcc10 (Mrp7) to in vivo paclitaxel resistance as assessed in Abcc10^−/− mice. Cancer Res. 71:3649–3657. 2011.PubMed/NCBI
24	Chen ZS, Hopper-Borge E, Belinsky MG, Shchaveleva I, Kotova E and Kruh GD: Characterization of the transport properties of human multidrug resistance protein 7 (MRP7, ABCC10). Mol Pharmacol. 63:351–358. 2003. View Article : Google Scholar : PubMed/NCBI
25	Carmichael J, DeGraff WG, Gazdar AF, Minna JD and Mitchell JB: Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res. 47:936–942. 1987.PubMed/NCBI
26	Zhou Y, Hopper-Borge E, Shen T, et al: Cepharanthine is a potent reversal agent for MRP7(ABCC10)-mediated multidrug resistance. Biochem Pharmacol. 77:993–1001. 2009. View Article : Google Scholar : PubMed/NCBI
27	Shi Z, Liang YJ, Chen ZS, et al: Reversal of MDR1/P-glycoprotein-mediated multidrug resistance by vector-based RNA interference in vitro and in vivo. Cancer Biol Ther. 5:39–47. 2006. View Article : Google Scholar : PubMed/NCBI
28	van den Heuvel-Eibrink MM, van der Holt B, Burnett AK, et al: CD34-related coexpression of MDR1 and BCRP indicates a clinically resistant phenotype in patients with acute myeloid leukemia (AML) of older age. Ann Hematol. 86:329–337. 2007.PubMed/NCBI
29	Wulf GG, Wang RY, Kuehnle I, et al: A leukemic stem cell with intrinsic drug efflux capacity in acute myeloid leukemia. Blood. 98:1166–1173. 2001. View Article : Google Scholar : PubMed/NCBI
30	Lainey E, Sebert M, Thepot S, et al: Erlotinib antagonizes ABC transporters in acute myeloid leukemia. Cell Cycle. 11:4079–4092. 2012. View Article : Google Scholar : PubMed/NCBI
31	Steinbach D and Legrand O: ABC transporters and drug resistance in leukemia: was P-gp nothing but the first head of the Hydra? Leukemia. 21:1172–1176. 2007. View Article : Google Scholar : PubMed/NCBI
32	Schaich M, Soucek S, Thiede C, Ehninger G and Illmer T: MDR1 and MRP1 gene expression are independent predictors for treatment outcome in adult acute myeloid leukaemia. Br J Haematol. 128:324–332. 2005. View Article : Google Scholar
33	List AF, Kopecky KJ, Willman CL, et al: Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study. Blood. 98:3212–3220. 2001. View Article : Google Scholar : PubMed/NCBI
34	Coley HM: Overcoming multidrug resistance in cancer: clinical studies of P-glycoprotein inhibitors. Methods Mol Biol. 596:341–358. 2010. View Article : Google Scholar : PubMed/NCBI
35	van der Holt B, Lowenberg B, Burnett AK, et al: The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis. Blood. 106:2646–2654. 2005.PubMed/NCBI
36	Tang R, Faussat AM, Perrot JY, et al: Zosuquidar restores drug sensitivity in P-glycoprotein expressing acute myeloid leukemia (AML). BMC Cancer. 8:512008. View Article : Google Scholar : PubMed/NCBI
37	Cortes JE, Pinilla-Ibarz J, le Coutre P, Paquette R, Chuah C, Nicolini FE, Apperley J and Khoury HJ: A pivotal phase 2 trial of ponatinib in patients with chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) resistant or intolerant to dasatinib or nilotinib, or with the T315I BCR-ABL mutation: 12-Month Follow-up of the PACE Trial J, 2012. https://ash.confex.com/ash/2012/webprogram/Paper48561.html.
38	Niu Q, Wang W, Li Y, et al: Low molecular weight heparin ablates lung cancer cisplatin-resistance by inducing proteasome-mediated ABCG2 protein degradation. PLoS One. 7:e410352012. View Article : Google Scholar : PubMed/NCBI
39	Han HK and Van Anh LT: Modulation of P-glycoprotein expression by honokiol, magnolol and 4-O-methylhonokiol, the bioactive components of Magnolia officinalis. Anticancer Res. 32:4445–4452. 2012.PubMed/NCBI
40	Tang SL, Chen WJ, Yin K, et al: PAPP-A negatively regulates ABCA1, ABCG1 and SR-B1 expression by inhibiting LXRα through the IGF-I-mediated signaling pathway. Atherosclerosis. 222:344–354. 2012.PubMed/NCBI
41	Wang H, Wang X, Li Y, et al: The proteasome inhibitor bortezomib reverses P-glycoprotein-mediated leukemia multi-drug resistance through the NF-κB pathway. Pharmazie. 67:187–192. 2012.PubMed/NCBI
42	Wang P, Zhang Z, Gao K, et al: Expression and clinical significance of ABCC10 in the patients with non-small cell lung cancer. Zhongguo Fei Ai Za Zhi. 12:875–878. 2009.(In Chinese).
43	Oguri T, Ozasa H, Uemura T, et al: MRP7/ABCC10 expression is a predictive biomarker for the resistance to paclitaxel in non-small cell lung cancer. Mol Cancer Ther. 7:1150–1155. 2008. View Article : Google Scholar : PubMed/NCBI
44	Borel F, Han R, Visser A, et al: Adenosine triphosphate-binding cassette transporter genes up-regulation in untreated hepatocellular carcinoma is mediated by cellular microRNAs. Hepatology. 55:821–832. 2012. View Article : Google Scholar